阿戈美拉汀对老年急性脑梗死伴焦虑抑郁障碍患者疗效的影响

Therapeutic impact of agomelatine in elderly patients with acute cerebral infarction and comorbid anxiety-depression disorders

目的探讨阿戈美拉汀通过调节血清神经递质和神经细胞因子对老年急性脑梗死伴焦虑抑郁障碍患者疗效的影响。方法选择2020年6月至2023年12月在萍乡市第二人民医院治疗的老年急性脑梗死合并焦虑抑郁障碍患者160例,患者均接受溶栓或介入治疗,随机数表法分为对照组80例和观察组80例。对照组接受常规心理干预,观察组在此基础上额外口服阿戈美拉汀片。比较2组认知功能、神经功能、神经递质、神经细胞因子、焦虑和抑郁评分、睡眠质量、生活质量和日常活动能力及不良反应的差异。结果2组干预后,简易智能状态检查量表(MMSE)评分、神经肽Y(NPY)、5-羟色胺(5-HT)、去甲肾上腺素(NE)、多巴胺、脑源性神经营养因子(BDNF)水平、36项简明健康调查问卷(SF-36)评分、Barthel指数量表评分高于干预前(P<0.01);且观察组干预后,MMSE评分、NPY、5-HT、NE、多巴胺、BDNF水平、SF-36评分、Barthel指数量表评分高于对照组(P<0.01)。2组干预后,美国国立卫生研究院卒中量表(NIHSS)评分、S100钙结合蛋白B(S100B)、髓鞘基本蛋白(MBP)水平、汉密尔顿焦虑量表(HAMA)评分、汉密尔顿抑郁量表17项版本(HAMD-17)评分、匹兹堡睡眠质量指数量表(PSQI)评分低于干预前(P<0.01);且观察组干预后,NIHSS评分、S100B、MBP水平、HAMA评分、HAMD-17评分、PSQI评分低于对照组(P<0.01)。观察组和对照组治疗期间总不良反应发生率比较,差异无统计学意义(3.75%vs 6.25%,χ~2=0.526,P=0.468)。结论阿戈美拉汀片应用于急性脑梗死合并焦虑抑郁障碍患者,可有效恢复认知功能,增强神经功能,改善睡眠质量和生活质量,优化日常生活能力,消除负面情绪,纠正神经递质和神经细胞因子表达。

Objective To investigate the effect of agomelatine on the clinical efficacy in elderly patients with acute cerebral infarction(ACI)and comorbid anxiety-depression disorders by regulating serum neurotransmitters and nerve cytokines.Methods A total of 160 elderly ACI patients with anxiety and depression symptoms admitted in Pingxiang Second People's Hospital from June 2020 to December 2023 were enrolled in this study.All of them received thrombolysis or interventional therapy,and then were randomly divided into control and observation groups,with 80 patients in each group.The control group received conventional psychological intervention,while the observation group was given additional oral administration of agomelatine.Cognitive function,neurological function,neurotransmitters and neuronal cytokines,anxiety and depression scores,sleep quality,quality of life,daily activity ability and adverse reactions were compared between the two groups.Results After intervention,Mini Mental State Examination(MMSE)scores,levels of neuropeptide Y(NPY),5-hydroxytryptamine(5-HT),norepinephrine(NE),dopamine and brain-derived neurotrophic factor(BDNF),36-item Brief Health Questionnaire(SF-36)score,and Barthel index scale score were significantly higher in both 2 groups when compared with above indicators before the intervention(P<0.01).And the MMSE score,NPY,5-HT,NE,dopamine and BDNF levels,SF-36 score and Barthel index scale score were obviously higher in the observation group than the control group(P<0.01).Both groups obtained notably lower NIHSS score,S100 calcium binding protein B(S100B)and myelin basic protein(MBP)levels,Hamilton Anxiety Rating Scale(HAMA)score,and Hamilton Depression Rating Scale 17(HAMD-17)score and Pittsburgh Sleep Quality Index(PSQI)score after intervention(P<0.01).And the NIHSS score,S100B and MBP levels,HAMA score,HAMD-17 score,and PSQI score were statistically lower in the observation group than the control group(P<0.01).During the treatment process,no significant difference was observed in the incidence of total adverse reactions between the two groups(3.75%vs 6.25%,χ~2=0.526,P=0.468).Conclusion When agomelatine tablets are indicated for ACI patients with concomitant anxiety-depression disorders,they can effectively rehabilitate cognitive function,enhance neurological function,improve sleep quality and quality of life,optimize activities of daily living,eliminate negative emotions,and correct the expression of neurotransmitters and neurotrophic factors.